Out-of-pocket costs from diagnostic testing after prostate cancer screening are common and rising

Prostate-specific antigen (PSA) screening aims to identify men who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive (and expensive) diagnostic testing to establish a diagnosis. New research reveals that the out-of-pocket costs for such additional tests are substantial, common, and rising. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Abnormal screening tests (i.e., elevated PSA) warrant additional testing involving magnetic resonance imaging and/or prostate biopsies. High out-of-pocket costs for these tests-;including copayment, coinsurance, and deductibles-;may not only place a substantial burden on patients, but also may deter patients from going through with recommended screening.

To investigate the extent of such financial burdens, researchers analyzed information on 3,075,841 US privately insured men ages 55–69 years old who underwent PSA screening in 2010–2020. Among these men, 91,850 had a second PSA test and an elevated PSA, of which 40,329 (43.9%) underwent subsequent diagnostic testing.

Among the men who underwent subsequent testing, more than 75% experienced out-of-pocket costs. The median out-of-pocket costs rose substantially over the years of the study for patients undergoing biopsy only ($79 to $214), imaging only ($81 to $490), and imaging plus biopsy ($353 to $620).

In 2023, the American Cancer Society published a statement asserting that cancer screening is a multistep process, stressing that payers must eliminate out-of-pocket costs for all necessary diagnostic tests.

In the context of prostate cancer, this means that insurance companies should provide full coverage for imaging, prostate biopsy, and other recommended testing, if indicated by an abnormal prostate cancer screening test. We have seen this strategy successfully implemented in colorectal cancer screening, as part of a new addition to the Affordable Care Act. Thus, we recommend that policymakers and insurance companies offer full coverage for testing throughout the screening pathway and eliminate cost-sharing for patients."

Arnav Srivastava, MD, MPH, lead author of the University of Michigan, Ann Arbor

This study was led by Dr. Arnav Srivastava, Ms. Anca Tilea, Dr. David D. Kim, Dr. Vanessa K. Dalton, and Dr. A. Mark Fendrick.

Source:
Journal reference:

Srivastava, A., et al. (2024) Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. Cancer. doi.org/10.1002/cncr.35392.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cancer therapy may raise heart attack and stroke risks by disrupting immune regulation in arteries